GW Pharmaceuticals (GWPH) Gets Consensus Rating of “Buy” from Analysts

Stocks of GW Pharmaceuticals (NASDAQ:GWPH) have earned a consensus recommendation of “Buy” from the fourteen research analysts that are presently covering the share, 1 expert has recommended the share with a sell rating, around three have published a hold rating, eight have published a buy rating and 1 has given a strong buy rating to The corporation. the consensus 12 month price target among analysts that have covered the share in the previous year is $160.16.

Stocks of GW Pharmaceuticals (NASDAQ:GWPH) transacted up 0.49% on early Mon, reaching $100.74. 132,191 stocks of the company transacted hands. GW Pharmaceuticals has a 52 week low of $79.62 and a 52 week high of $137.88. the firms valuation is $2.55 B. Company’s 50 day SMA is $101.55 and its 200 day SMA is $115.09.

Many brokerage firms commented on The corporation. ValuEngine lifted GW Pharmaceuticals from a “sell” recommendation to a “hold” recommendation in a analysis report on Wed, Jun 21st. Maxim Group restated a “buy” recommendation and given a $135.00 target price on stock of GW Pharmaceuticals in a study analysis published on early Thur, May 25th. Zacks trimmed GW Pharmaceuticals from a “hold” recommendation to a “sell” recommendation in a analysis report on Mon, May 15th. BidaskClub lifted GW Pharmaceuticals from a “sell” recommendation to a “hold” recommendation in a analysis report on Wed, Jun 21st. Lastly, TheStreet dropped GW Pharmaceuticals from a “c-” recommendation to a “d+” recommendation in a analysis report on Wed, May 10th.

GW Pharmaceuticals (NASDAQ:GWPH) previously issued its fiscal periodic earnings information on early Tue, May 9th. The biopharmaceutical business posted ($1.70) EPS for the period, falling below brokerage firms expectations of ($1.50) by $0.20. The company posted earnings of $2.04 M for the period end, compared with brokerage expectations of $2.07 M. GW Pharmaceuticals had a negative net profit margin of 1,021.38% and a negative ROE of 22.81%. The company’s periodic earnings was down 23.0% compared with the same period in the prior year. for the same quarter previous year, firm posted ($0.06) EPS. experts anticipate that GW Pharmaceuticals to post ($5.34) EPS for the present financial year.

Many institutional investors have modified to their stake in GWPH. Envestnet Asset Management boosted its position in stocks of GW Pharmaceuticals by 23.7% in the Q4. Envestnet Asset Management has an ownership of 1,376 stocks of the biopharmaceutical firms shares valued $154,000 after scooping up an extra 264 shares through out the previous quarter, Blair William IL acquired a new position in stocks of GW Pharmaceuticals during the Q1 valued roughly $207,000. Nwam acquired a new position in stocks of GW Pharmaceuticals during the Q1 valued roughly $208,000. Ladenburg Thalmann Financial Services boosted its position in stocks of GW Pharmaceuticals by 8.0% in the Q4. Ladenburg Thalmann Financial Services has an ownership of 1,916 stocks of the biopharmaceutical firms shares valued $218,000 after scooping up an extra 142 shares through out the previous quarter, Lastly, Tudor Investment Et Al acquired a new position in stocks of GW Pharmaceuticals throughout the Q4 valued roughly $219,000. 75.65% of the shares is presently held by investment firms and many large funds.

LEAVE A REPLY

Please enter your comment!
Please enter your name here